CO4950524A1 - Inhibidores de acido nitrico sintasa - Google Patents

Inhibidores de acido nitrico sintasa

Info

Publication number
CO4950524A1
CO4950524A1 CO98000758A CO98000758A CO4950524A1 CO 4950524 A1 CO4950524 A1 CO 4950524A1 CO 98000758 A CO98000758 A CO 98000758A CO 98000758 A CO98000758 A CO 98000758A CO 4950524 A1 CO4950524 A1 CO 4950524A1
Authority
CO
Colombia
Prior art keywords
solvate
compound
formula
pharmaceutically acceptable
functional derivative
Prior art date
Application number
CO98000758A
Other languages
English (en)
Inventor
Richard Mansfield Beams
Martin James Drysdale
Karl Witold Franzman
Anthony Joseph Frend
Hodson Harold Francis
Richard Frahan Knowles
David Rees Drayl
David Alan Sawyer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO4950524A1 publication Critical patent/CO4950524A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un compuesto de la fórmula (I), o una sal, solvato, o derivado funcional fisiológicamente del mismo. Un método para la profilaxis o el tratamiento de la condición clínica en un mamífero, tal como un ser humano, para el cual un inhibidor de la óxido nítrico sintasa está indicado, caracterizado porque comprende la administración de una cantidad efectiva terapéuticamente de un compuesto de la fórmula (I) como se definió en cualquiera de las reivindicaciones 1 a 3, o una sal aceptable farmacéuticamente, solvato, o derivado funcional fisiológicamente del mismo.Un método de conformidad con la reivindicación 4, caracterizado porque la condición clínica es seleccionada de la artritis, el asma, el íleo, y la migraña.Un compuesto de la fórmula (I) de conformidad con las reivindicaciones 1 a 3 o una sal aceptable farmacéuticamente, solvato o derivado funcional fisiológicamente del mismo, caracterizado porque se lo utiliza en terapia médica.Una formulación farmacéutica, caracterizada porque comprende un compuesto de la fórmula (I) como se definió en cualquiera de las reivindicaciones 1 a 3 o una sal aceptable farmacéuticamente, solvato, o derivado del mismo funcional fisiológicamente, y un portador o excipiente aceptable farmacéuticamente, y opcionalmente uno o más de otros ingredientes terapéuticos.El uso de un compuesto de la fórmula (I) como se definió en cualquiera de las reivindicaciones 1 a 3 o una sal aceptable farmacéuticamente, solvato, o derivado del mismo funcional fisiológicamente, en la fabricación de un medicamento para la profilaxis o tratamiento de una condición clínica para la cual un inhibidor de la óxido nítrico sintasa está indicado.
CO98000758A 1997-01-13 1998-01-09 Inhibidores de acido nitrico sintasa CO4950524A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78340297A 1997-01-13 1997-01-13

Publications (1)

Publication Number Publication Date
CO4950524A1 true CO4950524A1 (es) 2000-09-01

Family

ID=25129141

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98000758A CO4950524A1 (es) 1997-01-13 1998-01-09 Inhibidores de acido nitrico sintasa

Country Status (35)

Country Link
EP (1) EP0958277B1 (es)
JP (1) JP3251301B2 (es)
KR (1) KR20000070070A (es)
CN (1) CN1149190C (es)
AP (1) AP1204A (es)
AR (1) AR011069A1 (es)
AT (1) ATE209183T1 (es)
AU (1) AU723095B2 (es)
BR (1) BR9806870B1 (es)
CA (1) CA2277877C (es)
CO (1) CO4950524A1 (es)
CY (1) CY2263B1 (es)
CZ (1) CZ293099B6 (es)
DE (1) DE69803272T2 (es)
DK (1) DK0958277T3 (es)
EA (1) EA002033B1 (es)
EE (1) EE04013B1 (es)
ES (1) ES2168737T3 (es)
HK (1) HK1021531A1 (es)
HU (1) HU226241B1 (es)
ID (1) ID21981A (es)
IL (1) IL130551A (es)
IS (1) IS1847B (es)
MY (1) MY117948A (es)
NO (1) NO312192B1 (es)
NZ (1) NZ336379A (es)
PE (1) PE44599A1 (es)
PL (1) PL189973B1 (es)
PT (1) PT958277E (es)
RS (1) RS49673B (es)
SK (1) SK283201B6 (es)
TR (1) TR199901680T2 (es)
TW (2) TW502010B (es)
WO (1) WO1998030537A1 (es)
ZA (1) ZA98179B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810299D0 (en) * 1998-05-15 1998-07-15 Glaxo Group Ltd Use of nitric oxide synthase inhibitors
GB9811599D0 (en) * 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
BR0109386A (pt) * 2000-03-24 2003-04-15 Pharmacia Corp Composto de amidino e sais deste útil como inibidores de sintase de óxido nìtrico
GB0031179D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
US20040235890A1 (en) * 2001-09-10 2004-11-25 Masaharu Komeno Remedies for allergic diseases
GB0214147D0 (en) * 2002-06-19 2002-07-31 Glaxo Group Ltd Formulations
CN1674885A (zh) * 2002-08-02 2005-09-28 法玛西雅公司 治疗和预防胃肠病症的方法
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
WO2006072599A2 (en) 2005-01-10 2006-07-13 Glaxo Group Limited Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
US8178573B2 (en) 2006-04-20 2012-05-15 Glaxo Group Limited Compounds
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
PT2046787E (pt) 2006-08-01 2011-06-15 Glaxo Group Ltd Compostos de pirazolo[3,4-b]piridina e sua utilização como inibidores de pde4
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
JP5502077B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規な化合物
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2408916A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012521762A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた神経成長因子β鎖（ＮＧＦβ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
TW201103892A (en) 2009-04-24 2011-02-01 Glaxo Group Ltd Compounds
JP2012524754A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド Ｃｒａｃチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド
US20120046286A1 (en) 2009-04-30 2012-02-23 Julie Nicole Hamblin Novel Compounds
DE102009050171A1 (de) 2009-10-21 2011-04-28 Msr-Office Gmbh Multifunktionseinheit
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
JP2013512878A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド 新規化合物
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5876051B2 (ja) 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
SI2614058T1 (sl) 2010-09-08 2015-10-30 Glaxosmithkline Intellectual Property Development Limited Polimorfi in soli N-(5-(4-(5-(((2R,6S)-2,6-dimetil-4-morfolinil)metil)-1,3-oksazol-2-il)- 1H-indazol-6-il)-2-(metiloksi)-3-piridinil)metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
EP2630127A1 (en) 2010-10-21 2013-08-28 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
MY176421A (en) 2013-09-22 2020-08-07 Sunshine Lake Pharma Co Ltd Substituted aminopyrimidine compounds and methods of use
WO2015148867A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
UY36117A (es) 2014-05-12 2016-01-08 Glaxosmithkline Ip No 2 Ltd Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CA3083040A1 (en) 2018-01-20 2019-07-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4085217A (en) * 1964-01-29 1978-04-18 L'oreal Process and cosmetic compositions for the treatment of skin and scalp
US4512979A (en) * 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
DE3260831D1 (en) * 1981-06-05 1984-10-31 Merck & Co Inc Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
FR2727111B1 (fr) * 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments

Also Published As

Publication number Publication date
JP3251301B2 (ja) 2002-01-28
HK1021531A1 (en) 2000-06-16
RS49673B (sr) 2007-11-15
IS1847B (is) 2003-02-07
IL130551A0 (en) 2000-06-01
SK283201B6 (sk) 2003-03-04
AU723095B2 (en) 2000-08-17
EE9900281A (et) 2000-02-15
ZA98179B (en) 1999-07-09
TW502010B (en) 2002-09-11
CY2263B1 (en) 2003-07-04
HU226241B1 (en) 2008-07-28
TW538021B (en) 2003-06-21
EA199900532A1 (ru) 2000-08-28
CN1149190C (zh) 2004-05-12
CA2277877A1 (en) 1998-07-16
WO1998030537A1 (en) 1998-07-16
YU31399A (sh) 2002-06-19
CA2277877C (en) 2008-01-08
AR011069A1 (es) 2000-08-02
PL189973B1 (pl) 2005-10-31
NZ336379A (en) 2001-01-26
IS5094A (is) 1999-06-25
DE69803272D1 (en) 2002-02-21
KR20000070070A (ko) 2000-11-25
EP0958277A1 (en) 1999-11-24
HUP0001539A2 (hu) 2000-11-28
BR9806870A (pt) 2000-04-18
EE04013B1 (et) 2003-04-15
NO993429L (no) 1999-07-12
PE44599A1 (es) 1999-05-05
MY117948A (en) 2004-08-30
NO312192B1 (no) 2002-04-08
ES2168737T3 (es) 2002-06-16
DK0958277T3 (da) 2002-02-18
EP0958277B1 (en) 2001-11-21
JP2000504041A (ja) 2000-04-04
ID21981A (id) 1999-08-19
AU6208398A (en) 1998-08-03
IL130551A (en) 2004-01-04
CZ248399A3 (cs) 1999-12-15
EA002033B1 (ru) 2001-12-24
BR9806870B1 (pt) 2009-05-05
HUP0001539A3 (en) 2003-01-28
NO993429D0 (no) 1999-07-12
AP9901603A0 (en) 1999-09-30
ATE209183T1 (de) 2001-12-15
TR199901680T2 (xx) 1999-09-21
AP1204A (en) 2003-09-15
PT958277E (pt) 2002-05-31
SK93399A3 (en) 2000-03-13
CZ293099B6 (cs) 2004-02-18
CN1249744A (zh) 2000-04-05
PL334368A1 (en) 2000-02-28
DE69803272T2 (de) 2002-07-18

Similar Documents

Publication Publication Date Title
CO4950524A1 (es) Inhibidores de acido nitrico sintasa
DE69914463D1 (en) Therapeutische chemokine rezeptor antagonisten
SE0100568D0 (sv) Compounds
GB2303629B (en) Hydroxamic acids and their use as metalloproteinase inhibitors
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
AR006598A1 (es) "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
SE9901573D0 (sv) New compounds
SE0100569D0 (sv) New compounds
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
ATE257704T1 (de) Pharmazeutische zusammensetzungen enthaltend norastemizol.
DE69927497D1 (de) Sulfonsäure- oder sulfonylamino-n-(heteroaralkyl)-azaheterozyklylamidverbindungen
FR2850023B1 (fr) Medicaments pour le systeme nerveux
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
SE0102440D0 (sv) New compound
SE0100566D0 (sv) Compounds
RU2007138263A (ru) Противовоспалительные соединения
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
NO912414L (no) Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling.
BR0206954A (pt) Processo de terapia para câncer
SE0101692D0 (sv) Compounds
CO5261624A1 (es) Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
ES2059204T3 (es) Derivados del acido hidroxamico inhibidores de lipoxigenasa.
AR010432A1 (es) Composiciones farmaceuticas que contienen acido ricinoleico y su uso para la terapia antiinflamatoria y analgesica